Paul Davis, MD
Vascular Surgery · Baton Rouge, LANPI 1538123534
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Medtronic at 27.7% of the total. 2025 is the largest year on record at $7,737, 3.1 times the $2,487 reported in 2019.
Across 211 payments — averaging $87.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Penumbra, Inc.$4K
- Endologix LLC$2K
- Cardiovascular Systems Inc.$2K
- Boston Scientific$596
- Philips North America LLC$589
- plus $4K from 28 others
Across 15 payments — averaging $957.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- W. L. Gore & Associates, Inc.$14K
- Amgen$5
What the payments were for
- Consulting fees$4502%
- Travel & lodging$10,20456%
- Food & beverage$7,73142%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 29 | $5,087 |
| Penumbra, Inc. | 7 | $3,531 |
| Endologix LLC | 18 | $2,498 |
| Cardiovascular Systems Inc. | 21 | $2,351 |
| Boston Scientific | 7 | $596 |
| Philips North America LLC | 10 | $589 |
| Johnson & Johnson | 24 | $544 |
| Inari Medical, Inc. | 8 | $490 |
| Smith+Nephew | 19 | $477 |
| W. L. Gore & Associates, Inc. | 4 | $348 |
| Abbott | 4 | $252 |
| Silk Road Medical, Inc. | 12 | $233 |
| Kerecis Limited | 3 | $221 |
| Angiodynamics, Inc. | 9 | $183 |
| Surmodics, Inc. | 4 | $163 |
| Mindray DS USA, Inc. | 1 | $101 |
| Bard Peripheral Vascular, Inc. | 2 | $91 |
| Camber Spine Technologies LLC | 1 | $90 |
| Pfizer | 5 | $87 |
| E.r. Squibb & Sons, L.L.C. | 5 | $72 |
| KCI USA, Inc. | 3 | $66 |
| Edwards Lifesciences | 1 | $36 |
| Contego Medical, Inc | 1 | $35 |
| Acist Medical Systems, Inc. | 1 | $35 |
| Terumo Medical Corporation | 2 | $32 |
| Solventum Corporation | 1 | $27 |
| Shockwave Medical, Inc | 2 | $27 |
| Lemaitre Vascular, Inc. | 1 | $22 |
| Sanara Medtech Inc. | 1 | $22 |
| Tactile Systems Technology Inc | 1 | $21 |
| Argon Medical Devices, Inc. | 1 | $18 |
| ALON Medical Technology | 1 | $16 |
| Livanova USA, Inc. | 1 | $13 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENDURANT IIS$4,254
- Indigo System$3,202
- Peripheral Orbital Atherectomy System$1,801
- ENDOCROSS Device$1,301
- Torus Stent Graft System$1,301
- Varithena Administration Pack$478
- Kerecis Omega3 SurgiClose$443
- Alto Abdominal Stent Graft System$401
- Azurion 7 M20$304
- FLOWTRIEVER CATHETER, S$250
- CT THROMBECTOMY SYSTEM KIT$250
- Penumbra System$249
- XARELTO$218
- JETI$184
- Diamondback Peripheral$162
- Diamondback Coronary$162
- GORE TAG Thoracic Endoprosthesis$156
- GORE VIABAHN VBX Balloon Expandable Endo$152
- Kerecis Omega3 GraftGuide$148
- Kerecis Omega3 Marigen$148
How this compares
$18,385 in reported general payments places this provider in the 75th percentile of 65 vascular surgery providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 50 | $33,645 |
| Cilostazol | 37 | $620 |
| ClopidogrelClopidogrel Bisulfate | 54 | $274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $544 | $33,64550 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 65 vascular surgery providers in Louisiana.
Other vascular surgery in Baton Rouge
- Michael Conners IiiBaton Rouge$70K
- James CravenBaton Rouge$65K
- Marvin WeaverBaton Rouge$58K
- London GuidryBaton Rouge$25K
- Gulrez MahmoodBaton Rouge$9K
- Matthew AbateBaton Rouge$9K
- Wajeeh IrfanBaton Rouge$7K
- Taylor GwinBaton Rouge$7K
- Madeline DillsBaton Rouge$5K
- James McNeilBaton Rouge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.